A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The study will examine which dose of YM178 is best in terms of efficacy, safety and
tolerability compared to placebo and compared to tolterodine, a marketed product.